Back to Browse Journals » International Journal of Nanomedicine » Volume 8 » Issue 1

Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells

Authors Kim DH, Jeong YI, Chung CW, Kim CH, Kwak TW, Lee HM, Kang DH

Published Date April 2013 Volume 2013:8(1) Pages 1697—1711

DOI http://dx.doi.org/10.2147/IJN.S43508

Received 31 January 2013, Accepted 18 March 2013, Published 30 April 2013

Do Hyung Kim,1,2,* Young-Il Jeong,1,* Chung-Wook Chung,1 Cy Hyun Kim,1,2 Tae Won Kwak,1 Hye Myeong Lee,1 Dae Hwan Kang1,2

1
National Research and Development Center for Hepatobiliary Cancer, Pusan National University Yangsan Hospital, 2School of Medicine, Pusan National University, Yangsan, Gyeongsangnam-do, South Korea

*These authors equally contributed to this work.

Background: Cholangiocarcinoma is a malignant tumor arising from the epithelium of the bile ducts. In this study, we prepared sorafenib-loaded biliary stents for potential application as drug-delivery systems for localized treatment of extrahepatic cholangiocarcinoma.
Methods: A sorafenib-coated metal stent was prepared using an electrospray system with the aid of poly(ε-caprolactone) (PCL), and then its anticancer activity was investigated using human cholangiocellular carcinoma (HuCC)-T1 cells in vitro and a mouse tumor xenograft model in vivo. Anticancer activity of sorafenib against HuCC-T1 cells was evaluated by the proliferation test, matrix metalloproteinase (MMP) activity, cancer cell invasion, and angiogenesis assay in vitro and in vivo.
Results: The drug-release study showed that the increased drug content on the PCL film induced a faster drug-release rate. The growth of cancer cells on the sorafenib-loaded PCL film surfaces decreased in a dose-dependent manner. MMP-2 expression of HuCC-T1 cells gradually decreased according to sorafenib concentration. Furthermore, cancer cell invasion and tube formation of human umbilical vein endothelial cells significantly decreased at sorafenib concentrations higher than 10 mM. In the mouse tumor xenograft model with HuCC-T1 cells, sorafenib-eluting PCL films significantly inhibited the growth of tumor mass and induced apoptosis of tumor cells. Various molecular signals, such as B-cell lymphoma (Bcl)-2, Bcl-2-associated death promoter, Bcl-x, caspase-3, cleaved caspase-3, Fas, signal transducer and activator of transcription 5, extracellular signal-regulated kinases, MMP-9 and pan-janus kinase/stress-activated protein kinase 1, indicated that apoptosis, inhibition of growth and invasion was cleared on sorafenib-eluting PCL films.
Conclusion: These sorafenib-loaded PCL films are effective in inhibiting angiogenesis, proliferation and invasion of cancer cells. We suggest that sorafenib-loaded PCL film is a promising candidate for the local treatment of cholangiocarcinoma.

Keywords: sorafenib, polycaprolactone, biliary stent, human cholangiocarcinoma cells, angiogenesis

A Letter the the Editor has been received and published for this article.

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Development and characterization of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA

Malhotra M, Tomaro-Duchesneau C, Saha S, Kahouli I, Prakash S

International Journal of Nanomedicine 2013, 8:2041-2052

Published Date: 21 May 2013

Biological evaluation of protein nanocapsules containing doxorubicin

Toita R, Murata M, Abe K, Narahara S, Piao JS, Kang JH, Ohuchida K, Hashizume M

International Journal of Nanomedicine 2013, 8:1989-1999

Published Date: 17 May 2013

Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4 nanoparticles in A549/DDP lung cancer cells in vitro and in vivo

Li K, Chen B, Xu L, Feng J, Xia G, Cheng J, Wang J, Gao F, Wang X

International Journal of Nanomedicine 2013, 8:1867-1877

Published Date: 9 May 2013

Particle platforms for cancer immunotherapy

Serda RE

International Journal of Nanomedicine 2013, 8:1683-1696

Published Date: 29 April 2013

Optimized formulation of solid self-microemulsifying sirolimus delivery systems

Cho W, Kim MS, Kim JS, Park J, Park HJ, Cha KH, Park JS, Hwang SJ

International Journal of Nanomedicine 2013, 8:1673-1682

Published Date: 26 April 2013

Anchoring of self-assembled plasmid DNA/ anti-DNA antibody/cationic lipid micelles on bisphosphonate-modified stent for cardiovascular gene delivery

Ma G, Wang Y, Fishbein I, Yu M, Zhang L, Alferiev IS, Yang J, Song C, Levy RJ

International Journal of Nanomedicine 2013, 8:1029-1035

Published Date: 10 March 2013